Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Tundra lists 3 Asthma, Chronic Obstructive Pulmonary Disease (COPD) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ENROLLING BY INVITATION

NCT05952999

Analysis of the Virtual Acute Care at Home Experience

The purpose of this study is to examine the implementation, intervention effectiveness, and dissemination of a digital acute care delivery model for improving selected health outcomes in the Hospital at Home population.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-17

1 state

Conditions
Infections
Heart Failure
+6
RECRUITING

NCT06661252

Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders

This research study is an observational, single site study quantifying expression of biomarkers of respiratory disease in nasal fluid using the ABEL microsampler device. The primary objective of this study is to compare biomarker expression between healthy controls and participants with respiratory disorders such as chronic obstructive pulmonary disorder (COPD), hayfever, chronic sinusitis, asthma and rhinitis.

Gender: All

Ages: 18 Years - Any

Updated: 2025-06-06

1 state

Chronic Obstructive Pulmonary Disease (COPD)
Asthma Patients
Asthma and Rhinitis
+7
RECRUITING

NCT06678191

Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting

The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and quality of life. Also, there is scarcity of data regarding the phenotypes of asthmatics who benefit the most from the use of fixed triple combinations.

Gender: All

Ages: 18 Years - Any

Updated: 2024-11-22

Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Asthma Bronchiale